Tau-directed approaches for the treatment of Alzheimers disease: Focus on leuco-methylthioninium

Expert Review of Neurotherapeutics

Volumn 16, Issue 3, 2016, Pages 259-277

  Seripa, Davide ^a   Solfrizzi, Vincenzo ^b   Imbimbo, Bruno P ^c   Daniele, Antonio ^d   Santamato, Andrea ^e   Lozupone, Madia ^b   Zuliani, Giovanni ^f   Greco, Antonio ^a   Logroscino, Giancarlo ^b   Panza, Francesco ^a,b  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c CHIESI FARMACEUTICI S P A   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e UNIVERSITY OF FOGGIA   (Italy)

^f UNIVERSITY OF FERRARA   (Italy)

Author keywords

Alzheimer's disease; dementia; immunotherapy; leucomethylthioninium; methylthioninium; microtubule stabilizing agents; tau aggregation inhibitors; tau phosphorylation inhibitors; tau protein; TRx0237

Indexed keywords

LEUCO METHYLTHIONINIUM BLUE; METHYLENE BLUE; NOOTROPIC AGENT; TAU PROTEIN; TRX 0237; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BRAIN BLOOD FLOW; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; FRONTAL VARIANT FRONTOTEMPORAL DEMENTIA; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MOLECULAR WEIGHT; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROTEIN PROCESSING; RANDOMIZED CONTROLLED TRIAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRUCTURE ACTIVITY RELATION; TREATMENT DURATION; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; PATHOLOGY;

ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; HUMANS; METHYLENE BLUE; TAU PROTEINS;

EID: 84959325967     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2016.1140039     Document Type: Review

References (197)

1. Alzheimers Association. 2015 Alzheimers disease facts and figures. Alzheimers Dement. 2015; 11 (3): 332-384
2. Schneider LS, Mangialasche F, Andreasen N, et al. Clinical trials and late-stage drug development for Alzheimers disease: an appraisal from 1984 to 2014. J Intern Med. 2014; 275 (3): 251-283
3. Frisardi V, Solfrizzi V, Imbimbo BP, et al. Towards disease-modifying treatment of Alzheimers disease: drugs targeting beta-Amyloid. Curr Alzheimer Res. 2010; 7 (1): 40-55
4. Panza F, Solfrizzi V, Imbimbo BP, et al. Amyloid-directed monoclonal antibodies for the treatment of Alzheimers disease: the point of no return? Expert Opin Biol Ther. 2014; 14 (10): 1465-1476
5. Wischik CM, Harrington CR, Storey JM. Tau-Aggregation inhibitor therapy for Alzheimers disease. Biochem Pharmacol. 2014; 88 (4): 529-539
6. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997; 18 (4): 351-357
7. Panza F, Frisardi V, Solfrizzi V, et al. Immunotherapy for Alzheimers disease: from anti-β-Amyloid to tau-based immunization strategies. Immunotherapy. 2012; 4: 213-238
8. Lace GL, Wharton SB, Ince PG A brief history of tau: the evolving view of the microtubule-Associated protein tau in neurodegenerative diseases. Clin Neuropathol. 2007; 26 (2): 43-58
9. Wischik CM, Novak M, Thøgersen HC, et al. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimers disease. Proc Natl Acad Sci USA. 1988; 85 (12): 4506-4510
10. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82 (4): 239-259
11. Braak H, Braak E. Evolution of the neuropathology of Alzheimers disease. Acta Neurol Scand. 1996; 94 (S165): 3-12
12. Braak H, Thal DR, Ghebremedhin E, et al. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011; 70 (11): 960-969
13. Mukaetova-Ladinska EB, Garcia-Siera F, Hurt J, et al. Staging of cytoskeletal and β-Amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimers disease. Am J Pathol. 2000; 157 (2): 623-636
14. Duyckaerts C. Tau pathology in children and young adults: can you still be unconditionally baptist? Acta Neuropathol. 2011; 121 (2): 145-147
15. Grober E, Dickson D, Sliwinski MJ, et al. Memory and mental status correlates of modified Braak staging. Neurobiol Aging. 1999; 20 (6): 573-579
16. Nelson PT, Alafuzoff I, Bigio EH, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012; 71 (5): 362-381
17. Clark CM, Xie S, Chittams J, et al. Cerebrospinal fluid tau and beta-Amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol. 2003; 60 (12): 1696-1702
18. Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimers disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013; 12 (2): 207-216
19. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimers disease. N Engl J Med. 2012; 367: 795-804
20. Young AL, Oxtoby NP, Daga P, et al A data-driven model of biomarker changes in sporadic Alzheimers disease. Brain. 2014; 137 (Pt 9): 2564-2577
21. Jack CR, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimers pathological cascade. Lancet Neurol. 2010; 9: 119-128
22. Aisen PS, Petersen RC, Donohue MC, et al. Clinical core of the Alzheimers disease neuroimaging initiative: progress and plans. Alzheimers Dement. 2010; 6 (3): 239-246
23. Grundke-Iqbal I, Iqbal K, Tung YC, et al. Abnormal phosphorylation of the microtubule-Associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A. 1986; 83 (13): 4913-4917
24. Goedert M, Spillantini MG, Cairns NJ, et al. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron. 1992; 8 (1): 159-168
25. Wischik CM, Novak M, Edwards PC, et al. Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A. 1988 Jul; 85 (13): 4884-4888
26. Novak M, Kabat J, Wischik CM. Molecular characterization of the minimal protease resistant tau unit of the Alzheimers disease paired helical filament. EMBO J. 1993; 12 (1): 365-370
27. Guillozet-Bongaarts AL, Garcia-Sierra F, Reynolds MR, et al. Tau truncation during neurofibrillary tangle evolution in Alzheimers disease. Neurobiol Aging. 2005; 26 (7): 1015-1022
28. Yan SD, Chen X, Schmidt AM, et al. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci U S A. 1994; 91 (16): 7787-7791
29. Ledesma MD, Bonay P, Avila J. Tau protein from Alzheimers disease patients is glycated at its tubulin-binding domain. J Neurochem. 1995; 65 (4): 1658-1664
30. Reynolds MR, Berry RW, Binder LI. Site-specific nitration and oxidative dityrosine bridging of the tau protein by peroxynitrite: implications for Alzheimers disease. Biochemistry. 2005; 44 (5): 1690-1700
31. Reynolds MR, Reyes JF, Fu Y, et al. Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimers disease and other tauopathies. J Neurosci. 2006; 26 (42): 10636-10645
32. Choudhary C, Kumar C, Gnad F, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009; 325 (5942): 834-840
33. Min S-W, Cho S-H, Zhou Y, et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron. 2010; 67 (6): 953-966
34. Arnold CS, Johnson GV, Cole RN, et al. The microtubule-Associated protein tau is extensively modified with O-linked N-Acetylglucosamine. J Biol Chem. 1996; 271 (46): 28741-28744
35. Liu F, Iqbal K, Grundke-Iqbal I, et al. O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimers disease. Proc Natl Acad Sci USA. 2004; 101 (29): 10804-10809
36. Perry G, Mulvihill P, Fried VA, et al. Immunochemical properties of ubiquitin conjugates in the paired helical filaments of Alzheimer disease. J Neurochem. 1989; 52 (5): 1523-1528
37. Iqbal K, Grundke-Iqbal I. Ubiquitination and abnormal phosphorylation of paired helical filaments in Alzheimers disease. Mol Neurobiol. 1991; 5 (2-4): 399-410
38. Kolarova M, García-Sierra F, Bartos A, et al. Structure and pathology of tau protein in Alzheimer disease. Int J Alzheimers Dis. 2012; 2012: 731526
39. Zhang Q, Zhang X, Sun A. Truncated tau at D421 is associated with neurodegeneration and tangle formation in the brain of Alzheimer transgenic models. Acta Neuropathol. 2009; 117 (6): 687-697
40. Saito M, Chakraborty G, Mao R-F, et al. Tau phosphorylation and cleavage in ethanol-induced neurodegeneration in the developing mouse brain. Neurochem Res. 2010; 35 (4): 651-659
41. Cohen TJ, Guo JL, Hurtado DE, et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun. 2011; 2: 252
42. Stadelmann C, Deckwerth TL, Srinivasan A, et al. Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimers disease. Evidence for apoptotic cell death. Am J Pathol. 1999; 155 (2): 1459-1466
43. Rohn TT, Rissman RA, Davis MC, et al. Caspase-9 activation and caspase cleavage of tau in the Alzheimers disease brain. Neurobiol Dis. 2002; 11 (2): 341-354
44. Kimura T, Fukuda T, Sahara N, et al. Aggregation of detergent-insoluble tau is involved in neuronal loss but not in synaptic loss. J Biol Chem. 2010; 285 (49): 38692-38699
45. Pritchard SM, Dolan PJ, Vitkus A, et al. The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics. J Cell Mol Med. 2011; 15 (8): 1621-1635
46. Arrasate M, Mitra S, Schweitzer ES, et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004; 431 (7010): 805-810
47. Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature. 2006; 443 (7113): 780-786
48. Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem. 2009; 284 (19): 12845-12852
49. Clavaguera F, Bolmont T, Crowther RA, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009; 11 (7): 909-913
50. de Calignon A, Polydoro M, Suárez-Calvet M, et al. Propagation of tau pathology in a model of early Alzheimers disease. Neuron. 2012; 73 (4): 685-697
51. Asuni AA, Boutajangout A, Quartermain D, et al. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci. 2007; 27 (34): 9115-9129
52. Masliah E, Rockenstein E, Adame A, et al. Effects of α-synuclein immunization in a mouse model of Parkinsons disease. Neuron. 2005; 46 (6): 857-868
53. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimers amyloid β-peptide. Nat Rev Mol Cell Biol. 2007; 8 (2): 101-112
54. Iqbal K, Liu F, Gong C-X, et al. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol. 2009; 118 (1): 53-69
55. Brunden KR, Trojanowski JQ, Lee VM. Advances in tau-focused drug discovery for Alzheimers disease and related tauopathies. Nat Rev Drug Discov. 2009; 8 (10): 783-793
56. Andorfer C, Acker CM, Kress Y, et al. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci. 2005; 25 (22): 5446-5454
57. de Calignon A, Spires-Jones TL, Pitstick R, et al. Tangle-bearing neurons survive despite disruption of membrane integrity in a mouse model of tauopathy. J Neuropathol Exp Neurol. 2009; 68 (7): 757-761
58. Roberson ED, Scearce-Levie K, Palop JJ, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimers disease mouse model. Science. 2007; 316 (5825): 750-754
59. Vossel KA, Zhang K, Brodbeck J, et al. Tau reduction prevents A{beta}-induced defects in axonal transport. Science. 2010; 330 (6001): 198
60. Rhein V, Song X, Wiesner A, et al. Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimers disease mice. Proc Natl Acad Sci USA. 2009; 106 (47): 20057-20062
61. Vershinin M, Carter BC, Razafsky DS, et al. Multiple-motor based transport and its regulation by tau. Proc Natl Acad Sci USA. 2007; 104 (1): 87-92
62. Morel M, Authelet M, Dedecker R, et al. Glycogen synthase kinase-3β and the p25 activator of cyclin dependent kinase 5 increase pausing of mitochondria in neurons. Neuroscience. 2010; 167 (4): 1044-1056
63. Ittner LM, Fath T, Ke YD, et al. Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc Natl Acad Sci USA. 2008; 105 (41): 15997-16002
64. Ittner LM, Ke YD, Gotz J. Phosphorylated tau interacts with c-Jun N-Terminal kinase interacting protein 1 (JIP1) in Alzheimer disease. J Biol Chem. 2009; 284 (31): 20909-20916
65. Eckert A, Schulz KL, Rhein V, et al. Convergence of amyloid-β and Tau pathologies on mitochondria in vivo. Mol Neurobiol. 2010; 41 (2-3): 107-114
66. Martin L, Latypova X, Wilson CM, et al. Tau protein kinases: involvement in Alzheimers disease. Ageing Res Rev. 2013; 12 (1): 289-309
67. Iqbal K, Gong C-X, Liu F. Microtubule-Associated protein tau as a therapeutic target in Alzheimers disease. Expert Opin Ther Targets. 2014; 18 (3): 307-318
68. Pedersen JT, Sigurdsson EM. Tau immunotherapy for Alzheimers disease. Trends Mol Med. 2015; 21 (6): 394-402
69. Anand K, Sabbagh M. Early investigational drugs targeting tau protein for the treatment of Alzheimers disease. Expert Opin Investig Drugs. 2015; 24 (10): 1355-1360
70. Khatoon S, Grundke-Iqbal I, Iqbal K. Brain levels of microtubule-Associated protein tau are elevated in Alzheimers disease: a radioimmuno-slot-blot assay for nanograms of the protein. J Neurochem. 1992; 59 (2): 750-753
71. Wen Y, Planel E, Herman M, et al. Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3b mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing. J Neurosci. 2008; 28 (10): 2624-2632
72. Tolosa E, Litvan I, Höglinger GU, et al A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord. 2014; 29 (4): 470-478
73. Del Ser T, Steinwachs KC, Gertz HJ, et al. Treatment of Alzheimers disease with the GSK-3 inhibitor tideglusib: a pilot study. J Alzheimers Dis. 2013; 33 (1): 205-215
74. Lovestone S, Boada M, Dubois B, et al A phase II trial of tideglusib in Alzheimers disease. J Alzheimers Dis. 2015; 45 (1): 75-88
75. Kins S, Crameri A, Evans DR, et al. Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice. J Biol Chem. 2001; 276 (41): 38193-38200
76. Voronkov M, Braithwaite SP, Stock JB. Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimers disease. Future Med Chem. 2011; 3 (7): 821-833
77. Medina M, Avila J. Further understanding of tau phosphorylation: implications for therapy. Expert Rev Neurother. 2015; 15 (1): 115-122
78. Wang X, Blanchard J, Kohlbrenner E, et al. The carboxy-Terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment. FASEB J. 2010; 24 (11): 4420-321
79. Landrieu I, Smet-Nocca C, Amniai L, et al. Molecular implication of PP2A and Pin1 in the Alzheimers disease specific hyperphosphorylation of Tau. PLoS One. 2011; 6 (6): e21521
80. Sontag J-M, Nunbhakdi-Craig V, Sontag E. Leucine carboxyl methyltransferase 1 (LCMT1)-dependent methylation regulates the association of protein phosphatase 2A and Tau protein with plasma membrane microdomains in neuroblastoma cells. J Biol Chem. 2013; 288 (38): 27396-27405
81. Butler D, Bendiske J, Michaelis M, et al. Microtubule-stabilizing agent prevents protein accumulation-induced loss of synaptic markers. Eur J Pharmacol. 2007; 562 (1-2): 20-27
82. Zhang B, Carroll J, Trojanowski JQ, et al. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci. 2012; 32 (11): 3601-3611
83. Cortice biosciences announces results from studies evaluating pipeline candidates TPI 287 and CRT 001 in preclinical models of tauopathies and Alzheimers disease; 2014 [cited 2015 Sep 28 ]. Available from: http://globenewswire.com/newsrelease/2014/11/12/682514/10107850/en/Cortice-Biosciences-Announces-Results-From-Studies-Evaluating-Pipeline-Candidates-TPI-287-And-CRT-001-in-Preclinical-Models-of-Tauopathies-And-Alzheimer-s-Disease.html
84. Bassan M, Zamostiano R, et al. Complete sequence of a novel protein containing a femtomolar-Activity-dependent neuroprotective peptide. J Neurochem. 1999; 72 (3): 1283-1293
85. Vulih-Shultzman I, Pinhasov A, Mandel S, et al. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J Pharmacol Exp Ther. 2007; 323 (2): 438-449
86. Gozes I, Giladi E, Pinhasov A, et al. Activity-dependent neurotrophic factor: intranasal administration of femtomolar-Acting peptides improve performance in a water maze. J Pharmacol Exp Ther. 2000; 293 (3): 1091-1098
87. Gozes I. NAP (davunetide) provides functional and structural neuroprotection. Curr Pharm Des. 2011; 17 (10): 1040-1044
88. Gozes I, Schirer Y, Idan-Feldman A, et al. NAP alpha-Aminoisobutyric acid (IsoNAP). J Mol Neurosci. 2014; 52 (1): 1-9
89. Boxer AL, Lang AE, Grossman M, et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014; 13: 676-685
90. Rosenmann H, Grigoriadis N, Karussis D, et al. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol. 2006; 63 (10): 1459-1467
91. Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci. 2010; 30 (49): 16559-16566
92. Kontsekova E, Zilka N, Kovacech B, et al. First-in-man tau vaccine targeting structural determinants essential for pathological tau-Tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimers disease model. Alzheimers Res Ther. 2014; 6 (4): 44
93. Theunis C, Crespo-Biel N, Gafner V, et al. Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau. P301L mice that model tauopathy. PLoS One. 2013; 8 (8): e72301
94. Boutajangout A, Ingadottir J, Davies P, et al. Passive immunization targeting pathological phospho-Tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem. 2011; 118 (4): 658-667
95. Congdon EE, Gu J, Sait HB, et al. Antibody uptake into neurons occurs primarily via clathrin-dependent Fcγ receptor endocytosis and is a prerequisite for acute tau protein clearance. J Biol Chem. 2013; 288 (49): 35452-35465
96. Gu J, Congdon EE, Sigurdsson EM. Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology. J Biol Chem. 2013; 288 (46): 33081-33095
97. Kontsekova E, Ivanovova N, Handzusova M, et al. Chaperone-like antibodies in neurodegenerative tauopathies: implication for immunotherapy. Cell Mol Neurobiol. 2009; 29 (6-7): 793-798
98. Taniguchi T, Sumida M, Hiraoka S, et al. Effects of different anti-Tau antibodies on tau fibrillogenesis: RTA-1 and RTA-2 counteract tau aggregation. FEBS Lett. 2005; 579 (6): 1399-1404
99. Zilka N, Kontsekova E, Novak M. Chaperone-like antibodies targeting misfolded tau protein: new vistas in the immunotherapy of neurodegenerative foldopathies. J Alzheimers Dis. 2008; 15: 169-179
100. Kontsekova E, Zilka N, Kovacech B, et al. Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimers disease. Alzheimers Res Ther. 2014; 6 (4): 45
101. Buée L, Bussière T, Buée-Scherrer V, et al. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev. 2000; 33 (1): 95-130
102. Collin L, Bohrmann B, Göpfert U, et al. Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimers disease. Brain. 2014; 137 (Pt 10): 2834-2846
103. Bright J, Hussain S, Dang V, et al. Human secreted tau increases amyloid-beta production. Neurobiol Aging. 2015; 36 (2): 693-709
104. Cisek K, Cooper GL, Huseby CJ, et al. Structure and mechanism of action of tau aggregation inhibitors. Curr Alzheimer Res. 2014; 11 (10): 918-927
105. Taniguchi S, Suzuki N, Masuda M, et al. Inhibition of heparin-induced Tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem. 2005; 280 (9): 7614-7623
106. Wobst HJ, Sharma A, Diamond MI, et al. The green tea polyphenol (-)-epigallocatechin gallate prevents the aggregation of tau protein into toxic oligomers at substoichiometric ratios. FEBS Lett. 2015; 589 (1): 77-83
107. Crowe A, Ballatore C, Hyde E, et al. High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. Biochem Biophys Res Commun. 2007; 358 (1): 1-6
108. Wischik CM, Edwards PC, Lai RY, et al. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A. 1996; 93 (20): 11213-11218
109. Chirita C, Necula M, Kuret J. Ligand-dependent inhibition and reversal of Tau filament formation. Biochemistry. 2004; 43 (10): 2879-2887
110. Necula M, Chirita CN, Kuret J. Cyanine dye N744 inhibits tau fibrillization by blocking filament extension: implications for the treatment of tauopathic neurodegenerative diseases. Biochemistry. 2005; 44 (30): 10227-10237
111. Chang E, Congdon EE, Honson NS, et al. Structure-Activity relationship of cyanine tau aggregation inhibitors. J Med Chem. 2009; 52 (11): 3539-3547
112. Pickhardt M, Biernat J, Khlistunova I, et al. N-phenylamine derivatives as aggregation inhibitors in cell models of tauopathy. Curr Alzheimer Res. 2007; 4 (4): 397-402
113. Bulic B, Pickhardt M, Mandelkow E-M, et al. Tau protein and tau aggregation inhibitors. Neuropharmacology. 2010; 59 (4-5): 276-289
114. Bulic B, Pickhardt M, Khlistunova I, et al. Rhodanine-based tau aggregation inhibitors in cell models of tauopathy. Angew Chem Int Ed Engl. 2007; 46 (48): 9215-9219
115. Schafer KN, Cisek K, Huseby CJ, et al. Structural determinants of Tau aggregation inhibitor potency. J Biol Chem. 2013; 288 (45): 32599-32611
116. Larbig G, Pickhardt M, Lloyd DG, et al. Screening for inhibitors of tau protein aggregation into Alzheimer paired helical filaments: a ligand based approach results in successful scaffold hopping. Curr Alzheimer Res. 2007; 4 (3): 315-323
117. Pickhardt M, Larbig G, Khlistunova I, et al. Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells. Biochemistry. 2007; 46: 10016-10023
118. Pickhardt M, Gazova Z, von Bergen M, et al. Anthraquinones inhibit tau aggregation and dissolve Alzheimers paired helical filaments in vitro and in cells. J Biol Chem. 2005; 280 (5): 3628-3635
119. Crowe A, Huang W, Ballatore C, et al. Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-Throughput screening. Biochemistry. 2009; 48 (32): 7732-7745
120. Ballatore C, Crowe A, Piscitelli F, et al. Aminothienopyridazine inhibitors of tau aggregation: evaluation of structure-Activity relationship leads to selection of candidates with desirable in vivo properties. Bioorg Med Chem. 2012; 20 (14): 4451-4461
121. Li W, Sperry JB, Crowe A, et al. Inhibition of tau fibrillization by oleocanthal via reaction with the amino groups of tau. J Neurochem. 2009; 110 (4): 1339-1351
122. Monti MC, Margarucci L, Riccio R, et al. Modulation of tau protein fibrillization by oleocanthal. J Nat Prod. 2012; 75 (9): 1584-1588
123. Casamenti F, Grossi C, Rigacci S, et al. Oleuropein aglycone: a possible drug against degenerative conditions. In vivo evidence of its effectiveness against Alzheimers disease. J Alzheimers Dis. 2015; 45 (3): 679-688
124. George RC, Lew J, Graves DJ. Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimers disease pathogenesis. J Alzheimers Dis. 2013; 36 (1): 21-40
125. Peterson DW, George RC, Scaramozzino F, et al. Cinnamon extract inhibits tau aggregation associated with Alzheimers disease in vitro. J Alzheimers Dis. 2009; 17 (3): 585-597
126. Paranjape SR, Chiang Y-M, Sanchez JF, et al. Inhibition of Tau aggregation by three Aspergillus nidulans secondary metabolites: 2,ω-dihydroxyemodin, asperthecin, and asperbenzaldehyde. Planta Med. 2014; 80 (1): 77-85
127. Calcul L, Zhang B, Jinwal UK, et al. Natural products as a rich source of tau-Targeting drugs for Alzheimers disease. Future Med Chem. 2012; 4 (13): 1751-1761
128. Gao J-M, Yang S-X, Qin J-C. Azaphilones: chemistry and biology. Chem Rev. 2013; 113 (7): 4755-4811
129. Paranjape SR, Riley AP, Somoza AD, et al. Azaphilones inhibit tau aggregation and dissolve tau aggregates in vitro. ACS Chem Neurosci. 2015; 6 (5): 751-760
130. Crowe A, James MJ, Lee VM, et al. Aminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation. J Biol Chem. 2013; 288 (16): 11024-11037
131. Morris G, Anderson G, Dean O, et al. The glutathione system: a new drug target in neuroimmune disorders. Mol Neurobiol. 2014; 50 (3): 1059-1084
132. Chang E, Honson NS, Bandyopadhyay B, et al. Modulation and detection of tau aggregation with small-molecule ligands. Curr Alzheimer Res. 2009 Oct; 6 (5): 409-414
133. Bulic B, Pickhardt M, Mandelkow E. Progress and developments in tau aggregation inhibitors for Alzheimer disease. J Med Chem. 2013; 56 (11): 4135-4155
134. Ahmad B, Chen Y, Lapidus LJ. Aggregation of α-synuclein is kinetically controlled by intramolecular diffusion. Proc Natl Acad Sci U S A. 2012; 109 (7): 2336-2341
135. Ahmad B, Lapidus LJ. Curcumin prevents aggregation in α-synuclein by increasing reconfiguration rate. J Biol Chem. 2012; 287 (12): 9193-9199
136. Dolai S, Shi W, Corbo C, et al. "Clicked" sugar-curcumin conjugate: modulator of amyloid-β and tau peptide aggregation at ultralow concentrations. ACS Chem Neurosci. 2011; 2 (12): 694-699
137. Sinha S, Lopes DH, Du Z, et al. Lysine-specific molecular tweezers are broad-spectrum inhibitors of assembly and toxicity of amyloid proteins. J Am Chem Soc. 2011; 133 (42): 16958-16969
138. Attar A, Ripoli C, Riccardi E, et al. Protection of primary neurons and mouse brain from Alzheimers pathology by molecular tweezers. Brain. 2012; 135 (12): 3735-3748
139. Acharya S, Safaie BM, Wongkongkathep P, et al. Molecular basis for preventing α-synuclein aggregation by a molecular tweezer. J Biol Chem. 2014; 289 (15): 10727-10737
140. Landau M, Sawaya MR, Faull KF, et al. Towards a pharmacophore for amyloid. PLoS Biol. 2011; 9 (6): e1001080
141. Akoury E, Gajda M, Pickhardt M, et al. Inhibition of tau filament formation by conformational modulation. J Am Chem Soc. 2013; 135 (7): 2853-2862
142. Masuda M, Suzuki N, Taniguchi S, et al. Small molecule inhibitors of alpha-synuclein filament assembly. Biochemistry. 2006; 45 (19): 6085-6094
143. Dähne S. Color and constitution: one hundred years of research. Science. 1978; 199 (4334): 1163-1167
144. Schirmer RH, Adler H, Pickhardt M, et al. Lest we forget you-methylene blue. Neurobiol Aging. 2011; 32 (12): 2325.e7-2325.e16
145. Wainwright M, Amaral L. The phenothiazinium chromophore and the evolution of antimalarial drugs. Trop Med Int Health. 2005; 10 (6): 501-511
146. Gaudette NF, Lodge JW. Determination of methylene blue and leucomethylene blue in male and female Fischer 344 rat urine and B6C3F1 mouse urine. J Anal Toxicol. 2005; 29 (1): 28-33
147. Coulibaly B, Zoungrana A, Mockenhaupt FP, et al. Strong gametocytocidal effect of methylene blue-based combination therapy against falciparum malaria: a randomised controlled trial. PLoS One. 2009; 4 (5): e5318
148. Harvey BH, Duvenhage I, Viljoen F, et al. Role of monoamine oxidase, nitric oxide synthase and regional brain monoamines in the antidepressant-like effects of methylene blue and selected structural analogues. Biochem Pharmacol. 2010; 80 (10): 1580-1591
149. Peter C, Hongwan D, Küpfer A, et al. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol. 2000; 56 (3): 247-250
150. Müller T. Methylene blue supravital staining: an evaluation of its applicability to the mammalian brain and pineal gland. Histopathology. 1998; 13 (4): 1019-1026
151. Baddeley TC, McCaffrey J, Storey JM, et al. Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimers disease. J Pharmacol Exp Ther. 2015; 352 (1): 110-118
152. Harrington CR, Storey JM, Clunas S, et al. Cellular models of aggregation-dependent template-directed proteolysis to characterize Tau aggregation inhibitors for treatment of Alzheimer disease. J Biol Chem. 2015; 290 (17): 10862-10875
153. Melis V, Magbagbeolu M, Rickard JE, et al. Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models. Behav Pharmacol. 2015; 26 (4): 353-368
154. Dickey C, Ash P, Klosak N, et al. Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression. Mol Neurodegeneration. 2006; 1: 6
155. Jinwal UK, Miyata Y, Koren J 3rd, et al. Chemical manipulation of Hsp70 ATPase activity regulates tau stability. J Neurosci. 2009; 29 (39): 12079-12088
156. OLeary J, Li Q, Marinec P, et al. Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. Mol Neurodegener. 2010; 5: 45
157. Congdon EE, Wu JW, Myeku N, et al. Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy. 2012; 8 (4): 609-622
158. Xie L, Li W, Winters A, et al. Methylene blue induces macroautophagy through 5 adenosine monophosphate-Activated protein kinase pathway to protect neurons from serum deprivation. Front Cell Neurosci. 2013; 7: 56
159. Akoury E, Pickhardt M, Gajda M, et al. Mechanistic basis of phenothiazine-driven inhibition of tau aggregation. Angewandte Chemie Int Ed. 2013; 52 (12): 3511-3515
160. Pfaffendorf M, Bruning TA, Batink HD, et al. The interaction between methylene blue and the cholinergic system. Br J Pharmacol. 1997; 122 (1): 95-98
161. Mayer B, Brunner F, Schmidt K. Inhibition of nitric oxide synthesis by methylene blue. Biochem Pharmacol. 1993; 45 (2): 367-374
162. Chies AB, Custódio RC, de Souza GL, et al. Pharmacological evidence that methylene blue inhibits noradrenaline neuronal uptake in the rat vas deferens. Pol J Pharmacol. 2003; 55 (4): 573-579
163. Vutskits L, Briner A, Klauser P, et al. Adverse effects of methylene blue on the central nervous system. Anesthesiology. 2008; 108 (4): 684-692
164. Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol. 2007; 152 (6): 946-951
165. Necula M, Breydo L, Milton S, et al. Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. Biochemistry. 2007; 46 (30): 8850-8860
166. Medina DX, Caccamo A, Oddo S. Methylene blue reduces aβ levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol. 2011; 21 (2): 140-149
167. Deiana S, Harrington CR, Wischik CM, et al. Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine. Psychopharmacology (Berl). 2009; 202 (1-3): 53-65
168. Riha PD, Rojas JC, Gonzalez-Lima F. Beneficial network effects of methylene blue in an amnestic model. Neuroimage. 2011; 54 (4): 2623-2634
169. Paban V, Manrique C, Filali M, et al. Therapeutic and preventive effects of methylene blue on Alzheimers disease pathology in a transgenic mouse model. Neuropharmacology. 2014; 76 (Pt A): 68-79
170. Mori T, Koyama N, Segawa T, et al. Methylene blue modulates β-secretase, reverses cerebral amyloidosis, and improves cognition in transgenic mice. J Biol Chem. 2014; 289 (44): 30303-30317
171. Zakaria A, Hamdi N, Abdel-Kader RM. Methylene blue improves brain mitochondrial ABAD functions and decreases Aβ in a neuroinflammatory Alzheimers disease mouse model. Mol Neurobiol. 2015. [Epub ahead of print]. doi: 10.1007/s12035-014-9088-8
172. Roy Choudhury G, Winters A, Rich RM, et al. Methylene blue protects astrocytes against glucose oxygen deprivation by improving cellular respiration. PLoS One. 2015; 10 (4): e0123096
173. Wen Y, Li W, Poteet EC, et al. Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. J Biol Chem. 2011; 286 (18): 16504-16515
174. Poteet E, Winters A, Yan LJ, et al. Neuroprotective actions of methylene blue and its derivatives. PLoS One. 2012; 7 (10): e48279
175. Stack C, Jainuddin S, Elipenahli C, et al. Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity. Hum Mol Genet. 2014; 23 (14): 3716-3732
176. Hochgräfe K, Sydow A, Matenia D, et al. Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-Aggregant human Tau. Acta Neuropathol Commun. 2015; 3: 25
177. Mohideen SS, Yamasaki Y, Omata Y, et al. Nontoxic singlet oxygen generator as a therapeutic candidate for treating tauopathies. Sci Rep. 2015; 5: 10821
178. Al Mansouri AS, Lorke DE, Nurulain SM, et al. Methylene blue inhibits the function of α7-nicotinic acetylcholine receptors. CNS Neurol Disord Drug Targets. 2012; 11 (6): 791-800
179. Visarius TM, Stucki JW, Lauterburg BH. Stimulation of respiration by methylene blue in rat liver mitochondria. FEBS Lett. 1997; 412 (1): 157-160
180. van Bebber F, Paquet D, Hruscha A, et al. Methylene blue fails to inhibit Tau and polyglutamine protein dependent toxicity in zebrafish. Neurobiol Dis. 2010 Sep; 39 (3): 265-271
181. Hosokawa M, Arai T, Masuda-Suzukake M, et al. Methylene blue reduced abnormal tau accumulation in P301L tau transgenic mice. PLoS One. 2012; 7 (12): e52389
182. Spires-Jones TL, Friedman T, Pitstick R, et al. Methylene blue does not reverse existing neurofibrillary tangle pathology in the rTg4510 mouse model of tauopathy. Neurosci Lett. 2014; 562: 63-68
183. Cavaliere P, Torrent J, Prigent S, et al. Binding of methylene blue to a surface cleft inhibits the oligomerization and fibrillization of prion protein. Biochim Biophys Acta. 2013; 1832 (1): 20-28
184. Yamashita M, Nonaka T, Arai T, et al. Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models. FEBS Lett. 2009; 583 (14): 2419-2424
185. Arai T, Hasegawa M, Nonoka T, et al. Phosphorylated and cleaved TDP-43 in ALS, FTLD and other neurodegenerative disorders and in cellular models of TDP-43 proteinopathy. Neuropathology. 2010; 30 (2): 170-181
186. Mackenzie IRA, Neumann M, Cairns NJ, et al. Novel types of frontotemporal lobar degeneration: beyond tau and TDP-43. J Mol Neurosci. 2011; 45 (3): 402-408
187. Sontag EM, Lotz GP, Agrawal N, et al. Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntingtons disease models. J Neurosci. 2012; 32 (32): 11109-11119
188. Wischik CM, Staff RT, Wischik DJ, et al. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimers disease. J Alzheimers Dis. 2015; 44 (2): 705-720
189. Rager T, Geoffroy A, Hilfiker R, et al. The crystalline state of methylene blue: a zoo of hydrates. Phys Chem Chem Phys. 2012; 14 (22): 8074-8082
190. Melis V, Zabke C, Stamer K, et al. Different pathways of molecular pathophysiology underlie cognitive and motor tauopathy phenotypes in transgenic models for Alzheimers disease and frontotemporal lobar degeneration. Cell Mol Life Sci. 2015; 72 (11): 2199-2222
191. Wang JZ, Grundke-Iqbal I, Iqbal K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurochem. 2007; 25 (1): 59-68
192. Medina M, Avila J. New insights into the role of glycogen synthase kinase-3 in Alzheimers disease. Expert Opin Ther Targets. 2014; 18 (1): 69-77
193. Min S-W, Chen X, Tracy TE, et al. Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat Med. 2015; 21: 1154-1162. doi: 10.1038/nm.3951
194. Sigurdsson EM. Tau immunotherapy and imaging. Neurodegener Dis. 2014; 13 (2-3): 103-106
195. Castillo-Carranza DL, Sengupta U, Guerrero-Muñoz MJ, et al. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci. 2014; 34 (12): 4260-4272
196. Sutphen CL, Jasielec MS, Shah AR, et al. Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age. JAMA Neurol. 2015; 72 (9): 1029-1042
197. Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimers disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013; 12 (10): 957-965